[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-359452-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-359452-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","additive-clinical-utility-of-microsatellite-instability-and-tumor-mutational-burden-to-predict-immune-checkpoint-inhibitor-effectiveness-in-metastatic-castration-resistant-prostate-cancer","Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer","","Study evaluates how microsatellite instability (MSI) and tumor mutational burden (TMB) jointly predict immune checkpoint inhibitor benefit in metastatic castration-resistant prostate cancer (mCRPC). Using a US-based deidentified Clinico-Genomic Database, patients with tissue-assessed MSI (tMSI) and TMB (tTMB) eligible for single-agent ICI were analyzed for time to next treatment (TTNT) and overall survival (OS). Results show tMSI-H is usually accompanied by tTMB-high, with both additive associations for improved outcomes, and blood-based MSI supports ICI prediction when tissue is unavailable.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/additive-clinical-utility-of-microsatellite-instability-and-tumor-mutational-burden-to-predict-immune-checkpoint-inhibitor-effectiveness-in-metastatic-castration-resistant-prostate-cancer/359452/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/additive-clinical-utility-of-microsatellite-instability-and-tumor-mutational-burden-to-predict-immune-checkpoint-inhibitor-effectiveness-in-metastatic-castration-resistant-prostate-cancer/359452.png","ImageObject",300,407,{"name":42,"@type":43},"\tCallum ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are MSI and TMB important for immune checkpoint inhibitor use in mCRPC?","Question",{"text":63,"@type":64},"Immune checkpoint inhibitors have limited efficacy in unselected mCRPC, while biomarker-defined subsets such as MSI-H and TMB-H are approved. The study addresses uncertainty about which signals predict benefit, including how MSI and TMB relate when used together.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study assess tissue and blood measures of MSI and TMB?",{"text":68,"@type":64},"It used a US-based deidentified Clinico-Genomic Database for tissue-assessed MSI (tMSI) and TMB (tTMB) status, based on an algorithm supporting an FDA-approved CDx for pembrolizumab. It additionally assessed outcomes linked to blood-based MSI (bMSI), including patients treated with single-agent ICI or taxane.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key findings on outcomes for patients with different MSI/TMB profiles?",{"text":72,"@type":64},"Among mCRPC patients, tMSI-H was nearly always accompanied by tTMB ≥10 mut/Mb. In ICI-treated patients, more favorable TTNT and OS were observed for tMSI-H with any TMB and for tTMB ≥10 without tMSI-H, compared with lower TMB profiles without tMSI-H.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},359452,1790180509,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer  \nNicolas Sayegh1,2, Ryon P. Graf3, Umang Swami1, Zeynep Irem Ozay1, Chadi Hage Chehade1, Julia A. Elvin3, Douglas Lin3, Julia C. F. Quintanilha3, Gerald Li3, Alan H. Bryce4, Rana R. McKay5, Jeffrey S. Ross3, Tian Zhang2, and Neeraj Agarwal1  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: Immune checkpoint inhibitors (ICI) have shown limited efficacy in unselected patients with metastatic castrationresistant prostate cancer (mCRPC) . However, ICIs are approved for biomarker-defined subsets: microsatellite instability–high (MSI-H) and/or high tumor mutational burden (TMB-H) . The efficacy of ICIs in TMB-H but not MSI-H disease remains unclear, and limited data exist evaluating ICI outcomes associated with blood-based MSI (bMSI) in mCRPC.\u003Cbr>Experimental Design: This study used the United States– based deidentified Flatiron Health–Foundation Medicine prostate cancer Clinico-Genomic Database. Patients with tissue-assessed MSI (tMSI) and TMB (tTMB) status by an algorithm supporting an FDA-approved CDx for pembrolizumab were included if treated with single-agent ICI. Separately, outcomes on ICI associated with bMSI were assessed, including if treated with singleagent ICI or taxane.\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Results: Among 2,965 patients with mCRPC, tMSI-H (3.2%) was nearly always also tTMB ≥10 mut/Mb (4.7%) . In 84 ICItreated patients, time to next treatment (TTNT) and overall survival (OS) were more favorable in tMSI-H with any TMB [TTNT HR, 0. 18; 95% confidence interval (CI), 0.09–0.37 and OS HR, 0.32; 95% CI, 0.15–0.66] and tTMB ≥10 without tMSI-H (TTNT HR, 0. 18; 95% CI, 0.04–0.48 and OS HR, 0.20; 95% CI, 0.05–0.77) compared with tTMB \u003C10 without tMSI-H group. In intrapatient assessments, patients with tTMB ≥10 had more favorable TTNT with subsequent ICI versus prior taxane. Detection of bMSI-H was associated with more favorable TTNT on ICI (HR, 0.34; 95% CI, 0.14–0.83) and OS (HR, 0.21; 95% CI, 0.06– 0.75) when tumor fraction ≥1% .\u003Cbr>Conclusions: These findings add support for tTMB and tMSI in predicting ICI monotherapy benefit in mCRPC and provide evidence supporting bMSI testing when tissue is unavailable. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nMetastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease despite advancements in systemic therapy. Androgen receptor pathway inhibitors, taxane-based chemotherapy, PARP  \n1Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. 2Division of Hematology and Oncology, Department of Internal Medicine, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas. 3Foundation","cbCaimznp1Y6JsYl","https://ap.wps.com/l/cbCaimznp1Y6JsYl","pdf",2931250,12,"English","# Purpose\n# Experimental Design\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"Why are MSI and TMB important for immune checkpoint inhibitor use in mCRPC?\",\"answer\":\"Immune checkpoint inhibitors have limited efficacy in unselected mCRPC, while biomarker-defined subsets such as MSI-H and TMB-H are approved. The study addresses uncertainty about which signals predict benefit, including how MSI and TMB relate when used together.\"},{\"question\":\"How did the study assess tissue and blood measures of MSI and TMB?\",\"answer\":\"It used a US-based deidentified Clinico-Genomic Database for tissue-assessed MSI (tMSI) and TMB (tTMB) status, based on an algorithm supporting an FDA-approved CDx for pembrolizumab. It additionally assessed outcomes linked to blood-based MSI (bMSI), including patients treated with single-agent ICI or taxane.\"},{\"question\":\"What were the key findings on outcomes for patients with different MSI/TMB profiles?\",\"answer\":\"Among mCRPC patients, tMSI-H was nearly always accompanied by tTMB ≥10 mut/Mb. In ICI-treated patients, more favorable TTNT and OS were observed for tMSI-H with any TMB and for tTMB ≥10 without tMSI-H, compared with lower TMB profiles without tMSI-H.\"}]","Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer | PDF",1790136928,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b00c908306910845128d4bf5f8bf25bb.webp",983,1315,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50f8b69fb6b10b1af3dd8653e6318e57.webp",982,1314,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/230cf0140e9b3ee68f14bbc227db2692.webp",981,1312,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b47e7e322f8e6f889033d5262109419a.webp",980,1311]